Potential and limitations of regulatory T-cell therapy in solid organ transplantation.

Détails

ID Serval
serval:BIB_C2227C794334
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Potential and limitations of regulatory T-cell therapy in solid organ transplantation.
Périodique
Expert Review of Clinical Immunology
Auteur(s)
Govender L., Pascual M., Golshayan D.
ISSN
1744-8409 (Electronic)
ISSN-L
1744-666X
Statut éditorial
Publié
Date de publication
2014
Volume
10
Numéro
9
Pages
1197-1212
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
Over the past few years, the therapeutic potential of Treg has been highlighted in the field of autoimmune diseases and after allogeneic transplantation. The first hurdle for the therapeutic use of Treg is their insufficient numbers in non-manipulated individuals, in particular when facing strong immune activation and expanding effector cells, such as in response to an allograft. Here we review current approaches being explored for Treg expansion in the perspective of clinical therapeutic protocols. We describe different Treg subsets that could be suitable for clinical application, as well as discuss factors such as the required dose of Treg, their antigen-specificity and in vivo stability, that have to be considered for optimal Treg-based immunotherapy in transplantation. Since Treg may not be sufficient as stand-alone therapy for solid organ transplantation in humans, we draw attention to possible hurdles and combination therapy with immunomodulatory drugs that could possibly improve the in vivo efficacy of Treg.
Pubmed
Web of science
Création de la notice
30/09/2014 15:05
Dernière modification de la notice
20/08/2019 15:37
Données d'usage